Sofia Valenciano

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Knee Osteoarthritis

Placebo Controlled

Top Venues

Infectious diseases and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Robert Buynak, Kevin Cannon, David DeAtkine, John Kirby, Lisa Usdan, Amit B Bhavsar, Catherine Gérard, Anastasia Kuznetsova, Amulya Jayadev, Hiwot Amare, Sofia Valenciano, Nadia Meyer
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65. Infectious diseases and therapy 13 (8) (2024)
Robert Buynak, Kevin Cannon, David DeAtkine, John Kirby, Lisa Usdan, Amit B Bhavsar, Catherine Gérard, Anastasia Kuznetsova, Amulya Jayadev, Hiwot Amare, Sofia Valenciano, Nadia Meyer
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65. Infectious diseases and therapy (2024)
Robert Buynak, Kevin Cannon, David DeAtkine, John Kirby, Lisa Usdan, Amit B Bhavsar, Catherine Gérard, Anastasia Kuznetsova, Amulya Jayadev, Hiwot Amare, Sofia Valenciano, Nadia Meyer
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65. Infectious diseases and therapy 13 (8) (2024)
Robert Buynak, Kevin Cannon, David DeAtkine, John Kirby, Lisa Usdan, Amit B Bhavsar, Catherine Gérard, Anastasia Kuznetsova, Amulya Jayadev, Hiwot Amare, Sofia Valenciano, Nadia Meyer
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65. Infectious diseases and therapy 13 (8) (2024)